Mylan President, Others Engulfed in Price Fixing Ring (Audio) - podcast episode cover

Mylan President, Others Engulfed in Price Fixing Ring (Audio)

Nov 03, 20174 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Jennifer Rie, a senior litigation analyst for Bloomberg Intelligence, discusses a multiyear investigation by dozen of state attorneys general, which has revealed a global generic drug price fixing conspiracy, which has reached all the way to Mylan president Rajiv Malik. She speaks with Bloomberg's June Grasso and Michael Best on Bloomberg Radio's Bloomberg Law.

See omnystudio.com/listener for privacy information.

Transcript

Speaker 1

And now it's time for our Bloomberg Law Report. Let's get to the legal stories we're watching this morning with Adrian Mitchell and the Bloomberg One Washington news Room. Senate Republicans want to remove the fate of the Dreamers, undocumented immigrants brought to the US illegally as children, from the list of potential hurdles in urins bending talks. It would

be considered as separate legislation. Several of the biggest US companies, including Apple and Procter and Gamble, would no longer be able to escape taxes on the trillions and overseas profits they've accumulated under a tax bill released by House Republicans, and to develop new regulations. The FAA is looking for city, states and companies that want to test drones. Bloomberg Law everything you need, all on one legal research platform, including

guidance analysis and Bloomberg Market Intelligence. Find out more at Bloomberg Law dot com. Now, in other legal news, let's take a look at a multi year investigation by dozens of state attorneys general which has revealed a global price fixing conspiracy and the generic drug industry reaching all the way to the President of Myelon. For more on this story, Bloomberg lahou is doing Rosso and Michael Best speak with

Jennifer Ree, a senior litigation analyst for Bloomberg Intelligence. Jen, let's talk about some of the evidence, because it doesn't seem like there was a serious attempt to conceal the drugmaker's activities. You know, that's right, and on the outside, we're a little bit um. It's difficult to understand what all this evidence is because it's a very long complaint.

There's clearly a lot of evidence, but it's all redacted because this comes out of the company's emails, that comes out of the you know, transcripts of chat rooms, um and of eye texts. And the problem is that, you know, we don't really know what it says. But the Attorney General has said over and over again, even starting a year ago, that what they believe they've seen overwhelming evidence of a vast conspiracy and over arching conspiracy, conspiracy as

well as specific conspiracies among certain companies that had certain drugs. Jen, why would they feel the need to go individually after the executives of the companies rather than just suing the companies themselves. You know, I think it's a it's a it's a good question because they don't they don't necessarily necessarily have to do that. What they said here was that they believe this is a massive conspiracy. They believe that it is fairly blatant, and they want to hold

people responsible. So some of this could be just purely on principle, holding these executives responsible, but it also could be to put pressure on others perhaps to come in, you know, agree to cooperate. Well, Jen, you got forty five states. Are what kind of relief is it that they're going to want to see across all these companies. What they're seeking here is disgorgement of ill gotten gains.

So they're looking at what these companies, um, how they profited given the the art officially increased prices, and they're looking, you know, they're going to be protecting consumers in their own state as well as trying to get reimbursement for state governmental agencies um where those agencies might have overpaid for drugs. Remember that this is just one piece though, of sort of a triple threat against these companies, because they're also facing private class actions as well as the

Department of Justice investigation. So they may be fined as well as penalized if they end up with a judgment in the private actions or settle the private actions. That's Jennifer Ree, a senior litigation analyst for Bloomberg Intelligence, speaking with Bloomberg's Doom Grosso and Michael Best. You can listen to Bloomberg Law weekdays at one pm Wall Street Time here on Bloomberg Radio, and find more illegal news at Bloomberg Law dot com. Attorney so find exceptional legal research

and business development tools there as well. Visit Bloomberg Law dot com for more information.

Transcript source: Provided by creator in RSS feed: download file
For the best experience, listen in Metacast app for iOS or Android